The California Institute for Regenerative Medicine Science, Governance, and the Pursuit of Cures (2013) / Chapter Skim
Currently Skimming:
Appendix A: Data Sources and Methods
Appendix A: Data Sources and Methods
Pages 131-144
The Chapter Skim interface presents what we've algorithmically identified as the most significant single chunk of text within every page in the chapter.
Select key terms on the right to highlight them within pages of the chapter.
From page 131... ...
Valuable input also was obtained through CIRM's responses to the committee's data requests, three public meetings, two adjunct meetings, site visits to CIRM-funded research facilities, telephone interviews, and written public comments in response to online questionnaires targeting various stakeholders. The study was conducted over a 17-month period.
|
From page 132... ...
The third public meeting included presentations from individuals with varying perspectives on CIRM -- investigators who applied for but did not receive funding from the Institute, current Disease Team grantees, industry representatives, and a technology transfer officer. The agendas for the public meetings are presented in Boxes A-1 through A-3.
|
From page 133... ...
James Ellis, Department of Molecular Genetics, University of Toronto Andras Nagy, Samuel Lunenfeld Research Institute, Mount Sinai Hospital Janet Rossant, Department of Medical Genetics and Microbiology, University of Toronto Molly Shoichet, Department of Chemical Engineering and Applied Chemistry, University of Toronto (by phone) William Stanford, Department of Cellular and Molecular Medicine, University of Ottawa Peter Zandstra, Institute of Biomaterials and Biomedical Engineering, University of Toronto Boston Fernando Camargo, Stem Cell and Regenerative Biology, Harvard University Konrad Hochedlinger, Stem Cell and Regenerative Biology, Harvard University Jerome Ritz, Connell O'Reilly Cell Manipulation and Gene Transfer Laboratory, Dana-Farber Cancer Institute, Harvard Medical School Anthony Rosenzweig, Beth Israel Deaconess Medical Center, Harvard Medical School David Scadden, Stem Cell and Regenerative Biology, Harvard University Ramesh Shivdasani, School of Medicine, and Dana-Farber Cancer Institute, Harvard Medical School Les Silberstein, Joint Program in Transfusion Medicine, Harvard Medical School Amy Wagers, Stem Cell and Regenerative Biology, Harvard University
|
From page 134... ...
Paul Knoepfler, Department of Cell Biology and Human Anatomy, School of Medicine Kit Lam, Department of Biochemistry and Molecular Medicine, UC Davis Comprehensive Cancer Center Claire Pomeroy, CEO, UC Davis Health System and Dean of School of Medicine Mark Zern, Transplant Research Institute Min Zhao, Department of Dermatology, School of Medicine UCSF Arturo Alvarez-Bullya, Department of Neurological Surgery, Eli and Edythe Broad Center of Regenerative Medicine and Stem Cell Research Sam Hawgood, Dean of the UCSF School of Medicine and Vice Chancellor for Medical Affairs Diana Laird, Department of Obstetrics, Gynecology and Reproductive Sciences, UCSF Medical Center Daniel Lim, Department of Neurological Surgery, Eli and Edythe Broad Center of Regenerative Medicine and Stem Cell Research
|
From page 135... ...
, Germany George Daley, Stem Cell Transplantation at the Children's Hospital Kristen Doyle, Cancer Prevention and Research Institute of Texas Bill Gimson, Cancer Prevention and Research Institute of Texas Dan Gincel, Maryland Stem Cell Research Fund Zach W Hall, former president, CIRM Marianne Horn, Connecticut Department of Public Health
|
From page 136... ...
Intramural Center for Regenerative Medicine Beth Roxland, New York State Task Force on Life and the Law Christopher Scott, Stanford University School of Medicine Michael Stöcker, BMBF Lawrence S Sturman, New York State Stem Cell Science Alan Trounson, CIRM BOX A-1 Committee on a Review of the California Institute for Regenerative Medicine (CIRM)
|
From page 137... ...
The questionnaires were constructed for CIRM Independent Citizens Oversight Committee (ICOC) members, leadership from CIRM-funded institutions, CIRM principal investigators, university technology transfer professionals, investigators who applied for but did not receive funding from CIRM, CIRM for-profit industry partners, CIRM international partners, and stakeholders and members of the general public.
|
From page 138... ...
Roth CIRM Governing Board Vice Chair and Intellectual Property/Industry Subcommittee Member 11:40 a.m. OVERVIEW OF CIRM TRANSITION PLAN Jonathan Thomas, J.D., D.Phil.
|
From page 139... ...
and Delia B Baxter Professor Director, Baxter Laboratory for Stem Cell Biology Stanford University School of Medicine Frederick J
|
From page 140... ...
RECAP/DISCUSSION OF MORNING AND AFTERNOON PRESENTATIONS 4:00 p.m. PUBLIC COMMENT Individuals register for a slot and have 5 minutes for comments on any topic related to the study charge.
|
From page 141... ...
IOM Committee Chair 9:10 a.m. OVERVIEW OF LITTLE HOOVER COMMISSION REPORT Stuart Drown (by phone)
|
From page 142... ...
Associate Professor of Regenerative Medicine and Scientific Director in Cardiovascular and Neural Regeneration San Diego Regenerative Medicine Institute 12:45 p.m. PERSPECTIVES ON CIRM FROM DISEASE TEAM INVESTIGATORS Donald Kohn, M.D.
|
From page 143... ...
Technology Transfer Officer, Life Sciences, Office of Intellectual Property & Industry Sponsored Research University of California, Los Angeles 4:30 p.m. PUBLIC COMMENT Individuals register for a slot and have 5 minutes for comments on any topic related to the study charge.
|
Key Terms
This material may be derived from roughly machine-read images, and so is provided only to facilitate research.
More
information on Chapter Skim is available.